vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and N-able, Inc. (NABL). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $130.3M, roughly 1.5× N-able, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 11.8%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 7.0%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Able UK is a British industrial services company specialising in decommissioning of ships and offshore installations.
AXSM vs NABL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $130.3M |
| Net Profit | — | — |
| Gross Margin | — | 76.2% |
| Operating Margin | -33.1% | 10.2% |
| Net Margin | — | — |
| Revenue YoY | 57.4% | 11.8% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $130.3M | ||
| Q3 25 | $171.0M | $131.7M | ||
| Q2 25 | $150.0M | $131.2M | ||
| Q1 25 | $121.5M | $118.2M | ||
| Q4 24 | $118.8M | $116.5M | ||
| Q3 24 | $104.8M | $116.4M | ||
| Q2 24 | $87.2M | $119.4M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | $1.4M | ||
| Q2 25 | $-48.0M | $-4.0M | ||
| Q1 25 | $-59.4M | $-7.2M | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | $10.8M | ||
| Q2 24 | $-79.3M | $9.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 76.2% | ||
| Q3 25 | — | 77.5% | ||
| Q2 25 | — | 78.1% | ||
| Q1 25 | — | 76.6% | ||
| Q4 24 | — | 80.0% | ||
| Q3 24 | — | 82.9% | ||
| Q2 24 | — | 84.0% |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 10.2% | ||
| Q3 25 | -27.0% | 8.8% | ||
| Q2 25 | -24.5% | 7.7% | ||
| Q1 25 | -46.9% | 1.5% | ||
| Q4 24 | -61.1% | 13.7% | ||
| Q3 24 | -59.8% | 20.5% | ||
| Q2 24 | -89.5% | 18.4% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | 1.1% | ||
| Q2 25 | -32.0% | -3.1% | ||
| Q1 25 | -48.9% | -6.1% | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | 9.2% | ||
| Q2 24 | -91.0% | 7.9% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $-0.04 | ||
| Q3 25 | $-0.94 | $0.01 | ||
| Q2 25 | $-0.97 | $-0.02 | ||
| Q1 25 | $-1.22 | $-0.04 | ||
| Q4 24 | $-1.54 | $0.01 | ||
| Q3 24 | $-1.34 | $0.06 | ||
| Q2 24 | $-1.67 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $111.8M |
| Total DebtLower is stronger | $70.0M | $393.9M |
| Stockholders' EquityBook value | — | $804.7M |
| Total Assets | $713.6M | $1.4B |
| Debt / EquityLower = less leverage | — | 0.49× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $111.8M | ||
| Q3 25 | $325.3M | $101.4M | ||
| Q2 25 | $303.0M | $93.9M | ||
| Q1 25 | $300.9M | $94.1M | ||
| Q4 24 | $315.4M | $85.2M | ||
| Q3 24 | $327.3M | $174.4M | ||
| Q2 24 | $315.7M | $157.5M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $393.9M | ||
| Q3 25 | — | $331.7M | ||
| Q2 25 | — | $332.1M | ||
| Q1 25 | — | $332.6M | ||
| Q4 24 | — | $333.1M | ||
| Q3 24 | — | $333.6M | ||
| Q2 24 | — | $334.1M |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $804.7M | ||
| Q3 25 | $73.7M | $813.4M | ||
| Q2 25 | $73.1M | $809.4M | ||
| Q1 25 | $53.2M | $775.1M | ||
| Q4 24 | $57.0M | $759.3M | ||
| Q3 24 | $92.9M | $765.0M | ||
| Q2 24 | $102.9M | $724.4M |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $1.4B | ||
| Q3 25 | $669.3M | $1.4B | ||
| Q2 25 | $639.8M | $1.4B | ||
| Q1 25 | $596.7M | $1.4B | ||
| Q4 24 | $568.5M | $1.3B | ||
| Q3 24 | $561.5M | $1.2B | ||
| Q2 24 | $548.2M | $1.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.49× | ||
| Q3 25 | — | 0.41× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 0.44× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.46× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $25.3M |
| Free Cash FlowOCF − Capex | — | $20.9M |
| FCF MarginFCF / Revenue | — | 16.0% |
| Capex IntensityCapex / Revenue | — | 3.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $75.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $25.3M | ||
| Q3 25 | $1.0M | $24.0M | ||
| Q2 25 | $-32.4M | $24.2M | ||
| Q1 25 | $-43.4M | $19.7M | ||
| Q4 24 | $-26.2M | $26.0M | ||
| Q3 24 | $-18.6M | $22.0M | ||
| Q2 24 | $-30.1M | $27.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $20.9M | ||
| Q3 25 | $988.0K | $17.4M | ||
| Q2 25 | $-32.4M | $20.4M | ||
| Q1 25 | $-43.7M | $16.4M | ||
| Q4 24 | $-26.2M | $18.8M | ||
| Q3 24 | $-18.7M | $18.2M | ||
| Q2 24 | $-30.2M | $24.0M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 16.0% | ||
| Q3 25 | 0.6% | 13.2% | ||
| Q2 25 | -21.6% | 15.5% | ||
| Q1 25 | -36.0% | 13.9% | ||
| Q4 24 | -22.1% | 16.2% | ||
| Q3 24 | -17.9% | 15.7% | ||
| Q2 24 | -34.6% | 20.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 3.4% | ||
| Q3 25 | 0.0% | 5.0% | ||
| Q2 25 | 0.0% | 2.9% | ||
| Q1 25 | 0.3% | 2.8% | ||
| Q4 24 | 0.0% | 6.1% | ||
| Q3 24 | 0.1% | 3.2% | ||
| Q2 24 | 0.1% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 17.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.04× | ||
| Q2 24 | — | 2.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
NABL
| Transferred Over Time | $121.9M | 94% |
| Transferred At Point In Time | $8.4M | 6% |
| Other Revenue | $1.3M | 1% |
